A recent study identified chemerin as a negative regulator of HCC-associated inflammation and immunosuppression.22 Consistently, we reported that expression of chemerin in HCC was decreased compared to cancer-adjacent normal tissues, and chemerin treatment enhanced immune cell recruitment to the liver, restraining HCC progression. Here, RARRES2 is linked to cancer.